Skip Navigation

European Heart Journal 1995 16(Supplement D):33-37; doi:10.1093/eurheartj/16.suppl_D.33
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Molhoek, G. P.
Right arrow Articles by Takens, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molhoek, G. P.
Right arrow Articles by Takens, L. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK) Interim results

G. P. Molhoek, G. J. Laarman, D. J. A. Lok, C. M. Luz, J. H. Kingma, A. A. van den Bos, P. Zijnen, A. H. Bosma, D. P. Hertzberger and L. H. Takens

Working group on Cardiovasular research in The Netherland (WCN)

Correspondence: G. P. Molhoek, MD, R & D co-ordinator, Department of Cardiology Medisch Spectrum Twente, P.O. Box 50000, 7500 KA ENSCHEDE, The Netherlands.

To evaluate the efficacy and safety of hirudin, a direct thrombin inhibitor, in patients with acute myocardial infarction, a dose-finding, angiography study rvas carried out. After a pilot phase in 10 patients treated with a bolus of 0·1 mg . kg–1 and a continuous infusion of 0·06 mg . kg–1. h–1 (dose group I), two doses of hirudin, bolus 0·2 mg. kg–1. h–1 (DG II), and bolus 0.4 mg . kg–1 with 0·15 mg. kg–1. h–1 (DG III) were tested and compared with heparin as an adjunct to streptokinase and aspirin. This interim analysis was mandatory due to puncture-site related bleedings. Early and complete patency was achieved in 30% of 35 heparin patients in 40% of 10 DG I in 47% of 58 DG II and in 62% of 14 DG III patients. A dose-response relationship particularly between DG I and DG II was also observed in the anti-thrombotic activity monitored by the aPTT. Apart from the catheter-related bleedings, there were low rates of serious adverse events.

Key Words: Hirudin • thrombolysis • acute myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.